SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel ($INTC) is trending after a strong earnings report, beating expectations and forecasting continued growth. The community is discussing the potential for a short squeeze, the impact of government investments, and new partnerships. Many express confidence in the company's turnaround and future prospects in the semiconductor industry.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a recent pullback, prompting debate among investors about whether it represents a buying opportunity or a sign of deeper issues. Community discussions revolve around the stock's support levels, potential for a rebound, and the influence of broader market trends. Some investors remain confident in the company's long-term prospects within the AI and data center sectors, citing significant contracts and growth potential.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending amid speculation and a now-denied report about potential US government investment in quantum computing companies, fueling high trading volume. Community chatter focuses on whether this is a buying opportunity or a pump and dump scheme, while some highlight D-Wave's existing technology and government connections. The stock's volatility reflects broader interest and skepticism surrounding the quantum computing sector.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its fair launch and decentralized nature on the Bitcoin blockchain. Community members highlight its resilience during market corrections and tout the growing adoption by major players, like C2 Blockchain, accumulating $DOG for its treasury. The 'Dog Army' is actively pushing for broader exchange listings and celebrating its unique position within the Bitcoin ecosystem.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont (NEM) is trending as investors digest recent Q3 earnings, which beat expectations despite a drop in gold prices impacting the stock. Community discussions revolve around the CEO's performance on the earnings call and the potential for manipulation by HFs. Despite mixed sentiment, many see long-term value, citing strong earnings and revenue beats.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community debates the stock's reaction to recent earnings and future prospects, particularly regarding AI and robotics. Discussions include Elon Musk's compensation package and its potential impact, as well as speculation about market manipulation. Community sentiment is divided between bulls citing long-term potential and bears pointing to valuation concerns.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer's stock is trending downwards amidst community frustration over consistently missed revenue forecasts and concerns about management's credibility, despite reiterating strong long-term guidance. Discussions revolve around the impact of delayed orders and design upgrades on short-term performance versus the potential for significant revenue growth in future quarters. Some investors speculate about a potential acquisition due to the low share price and the company's bright future in the AI sector.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor (DECK) is trending as investors assess its future following recent earnings and guidance. Community discussions revolve around concerns about slowing growth and the potential impact of tariffs, despite a solid earnings report. Some see the dip as a buying opportunity, citing the company's strong brands and potential for stock buybacks, while others express caution due to market uncertainty and broader economic factors.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

B All In (BALLIN) is trending, with community members highlighting its strong momentum and potential for significant gains. The coin's association with Phantom Wallet and bullish chart patterns are key discussion points. Many users are expressing confidence and encouraging others to buy and hold.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

ALK is trending as investors await earnings, with some expressing concern over a potential delay in the release. Community members are analyzing option flows and debating whether bearish analysis will hold, or if the stock is poised for a pop. The airline sector's performance, including competitors like AAL, is also influencing sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey of the biopharmaceutical and...

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., Ionis chief executive officer, was awarded the 2025 Lifetime Achievement Award from the Oligonucleotide...

Ionis to hold third quarter 2025 financial results webcast

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, October 29th at 11:30 a.m. Eastern Time to discuss its third quarter 2025 financial results...

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL

FDA issues CRL to Biogen's regulatory filing seeking approval for a higher dose of SMA drug, Spinraza. The company plans prompt resubmission.

IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal

Ionis' zilganersen hits its phase III goal in Alexander disease, paving the way for a potential FDA filing in early 2026.

Several firms increased their price target on Ionis Pharmaceuticals (IONS) on Tuesday after the company announced positive results from a study of its Zilganersen drug in children and adults living with a rare neurological condition called Alexander disease (AxD).The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-pivotal-study">announced</a> on Tuesday that in the study, Zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization of the primary endpoint, gait speed, at week 61 compared to the control arm, with a favorable safety and tolerability profile. The company also said that Zilganersen indicated evidence of slowed disease progression, stabilization, or improvement.The firm intends to submit a new drug application to the U.S. Food and Drug Administration in the first quarter (Q1) of 2026. According to Ionis, Alexander Disease affects approximately one in one to three million people worldwide and has no approved disease-modifying treatments. The disease is characterized by progressive neurological deterioration, resulting in loss of functional mobility, independence, and the inability to control muscles for large movements, swallowing, and airway protection.Guggenheim on Tuesday raised its price target on the stock to $92 from $90, while maintaining a ‘Buy’ rating on the shares, according to TheFly. The new price target implies an upside of about 50% from the stock’s closing price on Monday.Other firms also hiked their price targets:<ol><li>Bank of America hiked its price target on IONS to $83 from $81 with a ‘Buy’ rating, while terming the news “an incremental positive” as Ionis could add another product to its expanding commercial portfolio.&nbsp;</li><li>Morgan Stanley hiked its price target on IONS to $86 from $71 while keeping an ‘Overweight’ rating on the shares.</li><li>Barclays also raised its price target on IONS to $80 from $78, with an ‘Overweight’ rating. The study results create a high probability of FDA approval, the analyst said.</li></ol>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IONS">IONS stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘low’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:574/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_23_at_11_39_52_AM_png_6ae39ea7d7.webp" alt="IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits" width="574" height="63"><figcaption>IONS' Sentiment Meter and Message Volume as of 11:40 a.m. ET on Sept. 23, 2025 | Source: Stocktwits</figcaption></figure>IONS' stock is up 80% this year and approximately 50% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-closes-probe-into-ford-bronco-vehicles-after-recent-recall/chDhCRLR35q">US Regulator Closes Probe Into Ford Bronco Vehicles – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ionis Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares. 

Equity

Guggenheim on Tuesday hiked the price target on the stock to $92 from $90 while keeping a ‘Buy’ rating on the shares. 


IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

Ionis jumps as FDA grants Breakthrough Therapy status to ION582 for treating Angelman syndrome, with the phase III study now underway.

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

Ionis Pharmaceuticals, Inc. (IONS) announced on Tuesday that its medicine, Olezarsen, reduced triglycerides and acute pancreatitis events in late-stage trials evaluating the drug in individuals with severe hypertriglyceridemia.Severe hypertriglyceridemia (sHTG) is defined by severely high triglycerides reaching into the thousands. It is characterized by an increased risk of acute pancreatitis and other morbidities. According to Ionis, approximately three million people are living with sHTG in the U.S., including more than one million who are considered high risk.In two <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ionis.com/news-releases/news-release-details/olezarsen-significantly-reduces-triglycerides-and-acute">studies</a>, Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months, as well as a highly statistically significant 85% reduction in acute pancreatitis events, with favorable safety and tolerability profiles. The two trials cumulatively enrolled nearly 1,100 patients who were required to be on standard-of-care lipid-lowering therapy throughout the treatment period.<a href="https://stocktwits.com/symbol/IONS">IONS stock</a> rocketed by 34% by Tuesday afternoon, reaching its February 2021 highs. On Stocktwits, retail sentiment around IONS jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_2_02_09_PM_png_166853294f.webp" alt="IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="59"><figcaption>IONS's Sentiment Meter and Message Volume as of 2:02 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the company’s future.<stembedurl>https://stocktwits.com/Mookins/message/627214651</stembedurl>Sam Tsimikas, senior vice president of global cardiovascular development at Ionis, termed the data “groundbreaking” and noted that the data reinforce the company’s confidence that the medicine has the potential to change how sHTG is treated. According to the firm, current standard of care therapies for sHTG and lifestyle modifications do not sufficiently or consistently lower triglyceride levels or reduce the risks of sHTG in all patients.Ionis plans to submit a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for approval of Olezarsen in sHTG by the end of the year. The drug is already approved in the U.S. as Tryngolza as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia (FCS).Several analysts hiked their price target on the stock following the news:<ul style="list-style-type:square;"><li>H.C. Wainwright raised its price target to $95 from $70 while keeping a ‘Buy’ rating on the shares. The firm also hiked its forecast for global Olezarsen sales up to $4.2 billion from $3.2 billion.</li><li>Jefferies raised its price target to $96 from $83 and kept a ‘Buy’ rating on the shares. The firm increased its estimate of Olezarsen's peak sales to about $2.5 billion from $1.5 billion due to higher assumed penetration in sHTG.&nbsp;</li><li>Barclays raised its target to $78 from $58, while keeping an ‘Overweight’ rating on the shares.</li><li>Morgan Stanley raised its price target to $71 from $62 and kept an ‘Overweight’ rating on the shares.</li></ul>IONS' stock is up 64% this year and approximately 21% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nio-expects-sales-bump-for-remainder-of-year-after-new-models-bring-strong-demand/chv6z3WRdFg">Nio Expects Sales Bump For Remainder Of Year After New Models Bring In Strong Demand: Retail Sees Stock Hitting At Least $10 By Year-End</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies 

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months. 

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

IONS
Ionis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IONS News

IONSIonis Pharmaceuticals Inc